Alzamend Neuro Statistics
Total Valuation
Alzamend Neuro has a market cap or net worth of $7.00 million. The enterprise value is $6.28 million.
| Market Cap | 7.00M |
| Enterprise Value | 6.28M |
Important Dates
The next estimated earnings date is Wednesday, September 9, 2026, after market close.
| Earnings Date | Sep 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Alzamend Neuro has 4.79 million shares outstanding. The number of shares has increased by 640.27% in one year.
| Current Share Class | 4.79M |
| Shares Outstanding | 4.79M |
| Shares Change (YoY) | +640.27% |
| Shares Change (QoQ) | +4.67% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 32.14% |
| Float | 4.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.47 |
| P/TBV Ratio | 9.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.31
| Current Ratio | 1.31 |
| Quick Ratio | 0.53 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,324.50 |
Financial Efficiency
Return on equity (ROE) is -373.18% and return on invested capital (ROIC) is -233.09%.
| Return on Equity (ROE) | -373.18% |
| Return on Assets (ROA) | -163.99% |
| Return on Invested Capital (ROIC) | -233.09% |
| Return on Capital Employed (ROCE) | -1,195.68% |
| Weighted Average Cost of Capital (WACC) | 5.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.46M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.87% in the last 52 weeks. The beta is 0.19, so Alzamend Neuro's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -37.87% |
| 50-Day Moving Average | 1.24 |
| 200-Day Moving Average | 1.68 |
| Relative Strength Index (RSI) | 63.89 |
| Average Volume (20 Days) | 50,928 |
Short Selling Information
The latest short interest is 328,289, so 6.85% of the outstanding shares have been sold short.
| Short Interest | 328,289 |
| Short Previous Month | 157,517 |
| Short % of Shares Out | 6.85% |
| Short % of Float | 6.88% |
| Short Ratio (days to cover) | 1.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.77M |
| Pretax Income | -8.77M |
| Net Income | -8.77M |
| EBITDA | -8.66M |
| EBIT | -8.77M |
| Earnings Per Share (EPS) | -$2.63 |
Balance Sheet
The company has $710,689 in cash and no debt, with a net cash position of $710,689 or $0.15 per share.
| Cash & Cash Equivalents | 710,689 |
| Total Debt | n/a |
| Net Cash | 710,689 |
| Net Cash Per Share | $0.15 |
| Equity (Book Value) | 733,211 |
| Book Value Per Share | 0.17 |
| Working Capital | 418,345 |
Cash Flow
| Operating Cash Flow | -8.07M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 110,740 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.07M |
| FCF Per Share | -$1.68 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Alzamend Neuro does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -640.27% |
| Shareholder Yield | -640.27% |
| Earnings Yield | -125.40% |
| FCF Yield | -115.33% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 12, 2025. It was a reverse split with a ratio of 1:9.
| Last Split Date | May 12, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |